
Expert view: Trump's tariffs may hit India's growth; Nifty to remain rangebound in August
The Indian stock market is anticipated to continue its range-bound to sideways trend in August.
Historically, August seasonal patterns have shown a limited upward trend. So yes, some near-term volatility may persist due to global uncertainty, weak FII flows and earnings downgrades.
However, structural fundamentals remain intact. A selective buy-on-dips approach, especially in quality large caps, could still work.
That's correct. Markets struggle to price in geopolitical risk, particularly given Trump's volatile stance.
As investors are aware that Trump regularly uses tariffs as a negotiating tool to secure more favourable trade agreements with major economies, the Indian stock market is currently undervaluing the potential impact of new tariffs.
In light of this uncertainty, market players hope that future talks between the USA and India will result in some relief in the form of a partial tariff reduction or easing.
Direct impact is limited as India isn't a primary target. But a broader global trade slowdown could weigh on exports and earnings.
Risk-off sentiment can also indirectly impact Indian equities. Trump's 25 per cent tariffs on Indian exports present a near-term headwind for the equity market, particularly for export-oriented sectors such as textiles, electronics, manufacturing, gems and automobiles.
The move could damage India's growth prospects, limiting foreign portfolio inflow and contributing to near-term volatility.
However, anticipated negotiations with the US may result in a partial reduction of tariffs, potentially providing some relief to investors' sentiment.
Q1 earnings, which presented a mixed picture across sectors, are largely in line with expectations.
While banks generally reported a contraction in NIMs after the recent rate cuts, the IT sector reported muted growth, reflecting ongoing challenges.
On the plus side, some industries, such as cement, renewable energy, and two-wheeler automobiles, are seeing strong volume growth.
Overall, the first quarter of FY26 has been a mixed earnings season, with some industries demonstrating resilience and others facing challenges.
We're constructive on rare earth materials, luxury and capital goods. These are supported by structural demand, policy tailwinds and shifting global supply chains.
A bottom-up approach in these segments can deliver solid returns. Renewable energy and associated industries like transmission, storage and module manufacturing will benefit from the clean energy transition.
Strong credit cycles, rising credit penetration and improving asset quality are all likely to contribute to banks and a few non-banking financial companies' (NBFCs') consistent earnings growth, making these industries attractive to Indian investors.
The IT Sector, traditionally with a long-term weightage in most portfolios, is under pressure from weak discretionary spending and longer decision cycles.
However, mid-cap IT players with strong digital capabilities and deal pipelines may outperform.
A large portion of the revenue is derived from global markets, especially the US, where corporates are delaying capex and expansion plans due to tariff and trade uncertainties.
Until global trade conditions stabilise, near-term growth is likely to remain subdued. However, the sector is on the cusp of an AI-driven transition, which is expected to unlock significant opportunities in automation, cloud and digital transformation.
As businesses worldwide accelerate their tech adoption and integrate AI into operations, dependence on Indian IT players for expertise, implementation, and support is likely to rise, reinforcing the sector's strategic importance in the global technology ecosystem.
Delayed rate cuts keep US yields and the dollar elevated, pressuring EM currencies and capital flows.
This tightens financial conditions, potentially impacting both bond and equity markets in the near term.
Foreign portfolio shifts towards emerging markets may be restrained if the dollar remains strong and US bond yields remain high due to an extended high-rate environment in the US.
Additionally, it might encourage central banks to limit rate cuts by continuing to take a cautious approach to domestic monetary easing.
Amidst the current scenario, the strategy could be to stay diversified with a tilt towards large caps and defensive stocks.
Use corrections to accumulate high-quality names with strong earnings visibility.
Maintain tactical cash reserves to capitalise on emerging opportunities.
Investors can consider adopting a buy-on-dips strategy rather than chasing short-term rallies.
While in the near term, many events are happening in August, such as GDP growth, inflation numbers, Trump's tariff decision, and Q1 earnings, which can heighten volatility in the upcoming period.
However, structural reforms, sound corporate balance sheets and strong domestic demand all contribute to India's continued resilience in its medium-term growth outlook.
So, investors might be able to better position themselves for possible upside once the momentum picks up by buying quality stocks during market corrections.
Read all market-related news here
Read more stories by Nishant Kumar
Disclaimer: This story is for educational purposes only. The views and recommendations expressed are those of individual analysts or broking firms, not Mint. We advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and circumstances may vary.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
19 minutes ago
- Economic Times
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'


Hans India
22 minutes ago
- Hans India
Vedanta continues winning street confidence: Brokerages forecast strong earnings ahead
New Delhi: Major global and Indian brokerages remain optimistic on Vedanta Ltd's performance for FY26, citing stronger LME pricing trends, cost discipline, deleveraging, and a resilient aluminium business among the key growth drivers. These firms have also taken note of the several growth projects scheduled for commissioning or completion in the next few quarters. JP Morgan noted that Vedanta's first quarter consolidated EBITDA was largely in line with estimates, with key segments such as aluminium, oil and gas, and power faring better than its expectations, leading to an overall segmental EBITDA beat. On the earnings trajectory for the current and next fiscal, the firm expects various ongoing initiatives at Vedanta to aid growth. "Vedanta's capacity expansion journey in the aluminium business as well as vertical integration should bring cost advantages. LME prices have also bottomed out and should continue to move higher into FY26-27, likely aiding earnings growth." Echoing similar views on LME prices and its potential benefit, Citi Research cited that Vedanta's parent (Vedanta Resources) leverage is at comfortable levels. It listed potential upside in medium-term aluminium LME prices, lower cost, and the demerger as another positive for Vedanta, while adding that aluminium globally has a limited supply growth. Mumbai-based Nuvama Institutional Equities expects Vedanta to deliver quarter-on-quarter EBITDA growth in Q2. "Q2FY26 EBITDA is likely to increase 10 per cent-plus quarter-on-quarter on the back of higher prices and lower aluminium cost of production. Major aluminium projects are likely to be commissioned in Q2FY26. We reckon net debt/EBITDA ex-Hindustan Zinc shall fall to 1.7x by FY26-end, compared to 2.7x in FY25. Demerger of the business is likely to be concluded in Q4FY26," the firm said in its report. The brokerage expects Vedanta's all major projects except coal blocks to be likely commissioned in the current fiscal, providing volume growth and cost reduction visibility for the company. UK-based Investec stated in its post-earnings report that Vedanta is a key beneficiary of depreciation in the Indian Rupee. Other near-term positives listed by the firm include declining alumina prices and the company offering attractive yields. The firm has retained its buy recommendation on Vedanta. Research firms like Kotak Institutional Equities and IIFL have cited factors like cost efficiencies and deleveraging at both Vedanta Ltd and its parent Vedanta Resources as beneficial factors. Vedanta's adjusted profit after tax jumped 13 per cent year-on-year to Rs 5,000 crore. The company clocked its highest-ever first-quarter EBITDA of Rs 10,746 crore, which was up 5 per cent year-on-year.


Indian Express
22 minutes ago
- Indian Express
Donald Trump eyes new Fed Chair as he calls for Jerome Powell's ouster
US President Donald Trump appears ready to push Federal Reserve Chair Jerome Powell out. The President, who has for months attacked the Federal Reserve Chair as 'stubborn,' signalled Tuesday that he is weighing a list of candidates to succeed Powell and may act soon. 'I didn't say I'm making a decision right now,' he told CNBC. But for anyone watching, the intent was clear: Trump wants Powell gone. Trump has long accused the central bank chief of refusing to lower interest rates in the face of economic slowdown and his own trade war. On Friday, after another disappointing jobs report, he went further, calling on the Fed's board of governors to override Powell. 'THE BOARD SHOULD ASSUME CONTROL,' Trump wrote on Truth Social, 'AND DO WHAT EVERYONE KNOWS HAS TO BE DONE!' The President's frustrations have coincided with a string of economic data that has not gone his way. Friday's nonfarm payrolls report showed just 73,000 jobs added in July – far below expectations – and included downward revisions of 258,000 for the previous two months. Hours later, Trump fired Erika McEntarfer, the commissioner of the Bureau of Labor Statistics, blaming her for 'the biggest miscalculations in over 50 years.' The move stunned economists. 'The risk of politicising the data collection process should not be overlooked,' warned Michael Feroli, JPMorgan Chase's chief US economist. 'Having a flawed instrument panel can be just as dangerous as having an obediently partisan pilot.' But if Trump is steering, he's also reshaping the cockpit. The resignation of Federal Reserve Governor Adriana Kugler, announced Friday, gives Trump a new opening. Kugler's term was set to run until January, but her early departure, combined with McEntarfer's firing, leaves Trump with two powerful vacancies to fill. And he's made it clear he knows the stakes. The Kugler vacancy, wrote Krishna Guha of Evercore ISI, 'jump-starts the Trumpification of the Fed by handing President Trump a vacancy into which he can place a potential or even a clearly designated successor to Powell as Fed chair.' Trump has hinted as much himself—saying his nominee for Kugler's post could well be the next chair when Powell's term expires in May 2026. He's also floated the possibility of pushing Powell out sooner, a move that would draw legal and political fire but has not been ruled out. Trump also ruled out Treasury Secretary Scott Bessent—'He's doing a great job, and he wants to do what he's doing'—but said he is evaluating 'Kevin and Kevin,' referring to former Fed Governor Kevin Warsh and National Economic Council Director Kevin Hassett. 'Both Kevins are very good,' Trump said. Two sitting Fed governors, Christopher Waller and Michelle Bowman, have already broken with Powell on interest rate policy. After Friday's meeting, both issued statements pushing for rate cuts and arguing that Trump's tariffs had only a one-time effect on inflation. Yet the Fed has held interest rates steady through 2025, and Powell has so far resisted Trump's repeated public pressure. The next chance for a rate cut comes in September.